NCT05518110View on ClinicalTrials.gov

PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

June 30, 2026

Conditions
Pancreatic Cancer
Interventions
DRUG

Trametinib

2mg of Trametinib (orally) daily.

DRUG

Hydroxychloroquine

1200mg of Hydroxychloroquine (orally; 600mg twice a day (BID)) daily.

Trial Locations (2)

D07 R2WY

RECRUITING

Mater Misericordiae University Hospital, Dublin

DO4 T6F4

RECRUITING

St Vincent's University Hospital, Dublin

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Cancer Trials Ireland

NETWORK

NCT05518110 - PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer | Biotech Hunter | Biotech Hunter